The role of the bronchial microvasculature in the airway remodelling in asthma and COPD

Andrea Zanini1*, Alfredo Chetta2, Andrea S Imperatori3, Antonio Spanevello1,4, Dario Olivieri2

Abstract
In recent years, there has been increased interest in the vascular component of airway remodelling in chronic bronchial inflammation, such as asthma and COPD, and in its role in the progression of disease. In particular, the bronchial mucosa in asthmatics is more vascularised, showing a higher number and dimension of vessels and vascular area. Recently, insight has been obtained regarding the pivotal role of vascular endothelial growth factor (VEGF) in promoting vascular remodelling and angiogenesis. Many studies, conducted on biopsies, induced sputum or BAL, have shown the involvement of VEGF and its receptors in the vascular remodelling processes. Presumably, the vascular component of airway remodelling is a complex multi-step phenomenon involving several mediators. Among the common asthma and COPD medications, only inhaled corticosteroids have demonstrated a real ability to reverse all aspects of vascular remodelling. The aim of this review was to analyze the morphological aspects of the vascular component of airway remodelling and the possible mechanisms involved in asthma and COPD. We also focused on the functional and therapeutic implications of the bronchial microvascular changes in asthma and COPD.

Introduction
Bronchial vessels usually originate from the aorta or intercostal arteries, entering the lung at the hilum, branching at the mainstem bronchus to supply the lower trachea, extrapulmonary airways, and supporting structures. They cover the entire length of the bronchial tree as far as the terminal bronchioles, where they anastomose with the pulmonary vessels. The bronchial vessels also anastomose with each other to form a double capillary plexus. The external plexus, situated in the adventitial space between the muscle layer and the surrounding lung parenchyma, includes venules and sinuses, and it constitutes a capacitance system. The internal plexus, located in the subepithelial lamina propria, between the muscularis and the epithelium, is essentially represented by capillaries. These networks of vessels are connected by short venous radicles, which pass through the muscle layer structure. The bronchial submucosal and adventitial venules drain into the bronchial veins which drain into the azygos and hemiazygos veins [1-3].

In normal airways, the bronchial microvasculature serves important functions essential for maintaining homeostasis. In particular, it provides oxygen and nutrients, regulates temperature and humidification of inspired air, as well as being the primary portal of the immune response to inspired organisms and antigens [4]. The high density of capillaries present is probably related to a high metabolic rate in the airway epithelium, which is very active in secretory processes. In fact, the oxygen consumption of airway epithelium is comparable to that of the liver and the heart [1]. In normal airways, the maintenance of vascular homeostasis is the result of a complicated interaction between numerous pro- and anti-angiogenetic factors (Table 1). Bronchial flow may be affected by alveolar pressure and lung volume, with higher airway pressures decreasing blood flow [5]. Moreover, the bronchial arteries have α- and β-adrenergic receptors and it is known that adrenaline, which has α-agonist effects, reduces total bronchial flow as it does in other systemic vascular beds [6]. Lastly, vagus stimulation may increase total bronchial flow [5].

During chronic inflammation, the vascular remodelling processes are the consequence of the prevalence of a pro-angiogenetic action, in which many growth factors and inflammatory mediators are involved [7]. Accordingly, the bronchial microvasculature can be modified by a
variety of pulmonary and airway diseases. Congestion of
the bronchial vasculature may narrow the airway lumen
in inflammatory diseases, and the formation of new bron-
chial vessels, angiogenesis, is implicated in the pathology
of a variety of chronic inflammatory, infectious, and
ischemic pulmonary diseases [3,4,8]. Bronchiectasis and
chronic airway infections may be characterized by hyper-
vascularity and neo-vascularisation of the airway walls
[9]. Additionally, airway wall ischemia following lung
transplantation can induce new vessel formation [9]. The
remarkable ability of the bronchial microvasculature to
undergo remodelling has also implications for disease pathogenesis.

| Angiogenic inducers | Angiogenic inhibitors |
|---------------------|----------------------|
| inflammatory mediators | soluble mediators |
| IL-3, IL-4, IL-5, IL-8, IL-9, IL-13 | IFN-α, IFN-β, IFN-γ |
| TNFα | Ang-2 |
| prostaglandins E1, E2 | TIMP-1, TIMP-2 |
| growth factors | VEGF |
| VEGF, FGF-1, FGF-2 | TGF-α, TGF-β |
| PDGF, PI GF | IGF |
| IGF | Protein fragments |
| COX-2 | Angiostatin |
| angiogenin | Endostatin |
| MMPs | angiogenin |
| hormones | DCC |
| estrogens | WT1 |
| gonadotropins | VHL |
| TSH | Proliferin |
| FGF-1, FGF-2 | Prolactin |
| Growth factors | VEGF |
| PDGF, TGF-β | TIMP-1, TIMP-2 |
| Prostaglandin E1, E2 | TSP-1, TSP-2 |
| VEGF | VEGI |
| FGF | PF-4 |
| IGF | Prolactin |
| COX-2 | Angiostatin |
| angiogenin | Endostatin |
| MMPs | angiogenin |
| hormones | DCC |
| estrogens | WT1 |
| gonadotropins | VHL |
| TSH | Proliferin |
| FGF-1, FGF-2 | Prolactin |
| Growth factors | VEGF |
| PDGF, TGF-β | TIMP-1, TIMP-2 |
| Prostaglandin E1, E2 | TSP-1, TSP-2 |
| VEGF | VEGI |
| FGF | PF-4 |
| IGF | Prolactin |
| COX-2 | Angiostatin |
| angiogenin | Endostatin |
| MMPs | angiogenin |
| hormones | DCC |
| estrogens | WT1 |
| gonadotropins | VHL |
| TSH | Proliferin |
| FGF-1, FGF-2 | Prolactin |
| Growth factors | VEGF |
| PDGF, TGF-β | TIMP-1, TIMP-2 |
| Prostaglandin E1, E2 | TSP-1, TSP-2 |
| VEGF | VEGI |
| FGF | PF-4 |
| IGF | Prolactin |

Most of the literature regarding bronchial vascular
remodelling in chronic airway inflammation results from
studies in asthmatic patients [10-15], since the vascular
component of airway remodelling significantly contribu-
tes to the alteration of the airway wall in asthma
(Figure 1). Interestingly, it has been recently shown that
bronchial vascular changes may also occur in COPD
[16-18]. Microvascular changes in asthma and COPD
may contribute to an increase in airway wall thickness
which may be associated with disease progression [9].
This review focuses on the morphological aspects of the
vascular component in airway wall remodelling in
asthma and COPD and its functional and therapeutic
implications.

Asthma
Early observations regarding bronchial vascular changes
in asthmatic airways date back to the sixties and con-
cern post-mortem analysis [19,20]. Dunnill and collea-
gues showed oedematous bronchial mucosa with dilated
and congested blood vessels in patients with fatal dis-
ease [19,20]. About thirty years later, some studies
demonstrated an increase in the percentage of blood
vessels in the airway walls; the concepts of vessel dilata-
tion, increased permeability and angiogenesis were
suggested [12,21].

Hyperaemia and hyperperfusion
An increased blood flow has been shown in the airways
of asthmatic patients, in comparison to healthy controls,
by measuring dimethyl ether in exhaled air [22]. Calcu-
lated as the volume of the conducting airways from the
trachea to the terminal bronchioles, mean airway blood
flow values were found to be 24-77% higher in asth-
matics than in healthy controls [22]. Increased blood
flow is likely due to the dilatation of arterioles and an
increased number of vessels.

Activation of pulmonary c-fibre receptors by irritants
and inflammatory mediators may induce vasodilatation
mainly via sympathetic motor nerves. Local axon
reflexes in response to irritants and inflammatory medi-
ators may release vasodilator neuropeptides such as
substance P, neurokinins, and calcitonin gene-related
peptides [23]. Consequently, the airway inflammation in
asthma may evoke mucosal vasodilatation due to the
direct action of mediators on vascular smooth muscle,
neuropeptides released by axon reflexes from sensory
nerve receptors, and reflex vasodilatation due to stimu-
lation of sensory nerves [23]. Nitric oxide (NO) and
blood flow regulation abnormalities by the sympathetic
nervous system may be involved in hyperaemia and
hyperperfusion, even if the precise mechanisms are
unclear [24]. Notably, bronchial blood flow positively
correlates with both exhaled nitric oxide NO and breath
temperature in asthmatic subjects [25]. Exhaled breath temperature and bronchial blood flow may reflect rubor and calor in the airways, and therefore may be markers of tissue inflammation and remodelling [25].

**Microvascular permeability**

Increased microvascular permeability and oedema are common features during vascular remodelling in bronchial asthma [26]. Electronic microscopy studies have shown that in the lower airways of most species, including healthy humans, only the capillaries underlying neuroepithelial bodies are fenestrated, the rest having a continuous epithelium [1]. By contrast, in some animal species the lower airway capillaries are fenestrated [27]. Interestingly, this feature is also observed in asthmatic patients [27]. Using animal models, McDonald et al [27] suggested a role for intercellular gaps between endothelial cells of postcapillary venules in microvascular permeability. Some reports confirmed the relevant presence of this phenomenon in airways of asthmatic patents [28-33]. In these studies, microvascular permeability was evaluated by the airway vascular permeability index as measured by the albumin in induced sputum/albumin in serum [28-31], or as fibronectin concentrations [32] or alpha 2-macroglobulin levels [33] in BAL fluid.

Plasma extravasations can compromise epithelial integrity and contribute to formation luminal mucus plugs [34]. Plasma leakage can also lead to mucosal oedema and bronchial wall thickening, thereby reducing the airway lumen, which in turn causes airflow limitation and may contribute to airway hyperresponsiveness [35,36]. Furthermore, during the chronic inflammation process, new capillaries are immature and unstable and can contribute to increased permeability [36]. The increased microvascular permeability is due to the release of inflammatory mediators, growth factors, neuropeptides, cytokines, eosinophil granule proteins, and proteases (Table 2).

Vascular endothelial growth factor (VEGF) is a potent angiogenic factor, proven to be increased in asthma and correlated to the vascular permeability of airways [28-30], as well as shown to determine gaps in the

| Table 2 Factors involved in the bronchial vasculature remodelling in asthma and COPD |
|---------------------------------|-----------------|----------------|
| Angiogenesis | Vasodilatation | Permeability |
| VEGF | VEGF | VEGF |
| FGF | Histamine | Histamine |
| TGFβ | Heparine | Adenosin |
| HGF | Tryptase | Bradykinin |
| HIF | NO | Ang-1, Ang-2 |
| Ang-1 | TGFα, TGFβ | SP |
| Histamine | FGF | CGRP |
| PGD2 | EGF | LTβ, LTC4, LTD4 |
| PGI2 | IL-4 | PAF |
| LTC2 | TNFα | ET-1 |
| PAF | LTC4 | TNFα |
| SP | PGD2 | ECP |
| VIP | IL-8, IL-13 | |
| TNFα | NKA | |
| Angiogenin | MMPs | |
| IGF-1 | Chymase | |
| VCAM-1 | E-selectin | |
| α,β3 | | |
endothelium [37]. Angiopoietin-1 is known to stabilize nascent vessels, making them leak resistant, while Angiopoietin-2 reduces vascular integrity. Angiopoietin-2, but not angiopoietin-1, is positively correlated to the airway vascular permeability index [31]. Greiff et al [38] found that histamine was able to induce plasma extravasation with consequent bronchial exudation in healthy subjects. Similarly, bradykinin can determine plasma exudation in human peripheral airways. Berman et al [39] performed BAL in airways of normal and asthmatic subjects before and after challenges with bradykinin, aerosolized through a bronchoscope. They observed an increase in fibrinogen levels in the BAL fluid from both groups, thereby suggesting bradykinin-induced microvascular leakage [39].

**Angiogenesis**

Unlike the pulmonary circulation, the bronchial vessels are known to have a considerable ability to proliferate during several pathological conditions. Leonardo da Vinci is generally regarded as the first person to observe, around a cavitative lesion in human lung, the presence of vascular phenomena, that could be interpreted as angiogenetic processes [40]. In the last two decades, many reports have documented angiogenesis of bronchial vessels in response to a wide variety of stimuli, including chronic airway inflammation. Angiogenesis can be defined as the formation of new vessels by sprouting from pre-existing vessels [41]. With a broad meaning, lengthening and enlargement of existing vessels are also considered to be angiogenesis, whereby the vessels take a more tortuous course.

To explore and quantify the bronchial microvasculature, different methodological approaches are possible. Biopsy specimens from post-mortem resections provide considerable amounts of tissue with good clinical characterisation [11,21]. Similarly, lung resection studies allow for harvesting of pulmonary tissue in reasonable quantities, even if the tying procedure at the resection margin could influence the bronchial vascular congestion [21]. Fiberoptic bronchoscopy offers the possibility of obtaining repeated samples from the same patients, with varying disease severity, and evaluating pharmacological effects [42]. Finally, high magnification video bronchoscopy, a more recent and less invasive technique, is also useful to study the bronchial microvascularity in asthma and COPD [43,44].

Immunohistochemical analysis represents the gold standard approach to quantify bronchial microvascularity. The quantification of bronchial vessels generally includes the number of vessels per square millimetre of area analyzed, the vascular area occupied by the vessels, expressed as percentage of the total area evaluated, and the mean vessel size, estimated by dividing the total vascular area by the total number of vessels [12,17,42,45,46].

Two studies used the monoclonal antibody against factor VIII and analyzed the entire submucosa, finding both an increase vascular areas and vessel dimensions in asthmatic patients in comparison to healthy controls [11,21]. Furthermore, to obtain a better identification of the bronchial microvascularity, some groups of authors used the monoclonal antibody against collagen type IV [12,42,45-47], and performed the quantification in the supepithelial lamina propria [12,42,45,47] or in the entire submucosa [46]. Except for the Orsida study [45], which showed that asthmatics had only an increase in vascular area when compared to healthy controls, the other studies found an increase both in vessel number and in vascular area [12,42,46]. Salvato stained his sections with a combination of haematoxylin-eosin, Masson trichrome, PAS, alcian blue-PAS and orcein, and evaluated microvessels in the suppepithelial lamina propria, showing an increase in vessel number and vascular area [13]. Moreover, some studies used the monoclonal antibody anti-CD31 [17,47,48], apparently more vessel-specific, but further investigation is required to obtain a better technique to measure the various aspects of angiogenesis [49].

In asthmatic patients, even with mild to moderate disease, a significant increase in the number of vessels and/or percent vascular area, as well as an increased average capillary dimension, can be observed in comparison to healthy controls [12,13,17,42,45-47]. Furthermore, a relationship between increased bronchial microvascularity and the severity of asthmatic disease was found [13,17,50]. Finally, the vascular component of airway remodelling in asthma does not appear related to the duration of the disease, given that it can be detectable even in asthmatic children [48].

Angiogenesis should be considered to be a complex multiphase process, potentially involving a great number of growth factors, cytokines, chemokines, enzymes and other factors (Table 2 and Figure 2). The specific role of each molecule has not been clearly defined, even if VEGF is considered to be the most important angiogenic factor in asthma [51]. Many biopsy studies [47,52-54], as well as reports conducted on induced sputum [28-31], have observed higher VEGF levels in asthmatic airways when compared to those of healthy controls. In particular, immunohistochemical studies demonstrated close relationships between VEGF expression and vascularity [47,52-54]. Hoshino et al [53] found an increased staining of mRNA for VEGF receptors (R1 and R2) on bronchial endothelium in asthmatic patients versus normal subjects. Feltis et al. [47] showed a relationship between VEGF and VEGF-R2 expression in asthma and between VEGF and VEGF-R1 in controls.
It is of note that VEGF-R2 is the major mediator of the mitogenic, angiogenic and permeability-enhancing effects of VEGF, while VEGF-R1 has been suggested to act as a modulating decoy to VEGF-R2, thereby inhibiting VEGF-VEGF-R2 binding [55]. Therefore, it is plausible that VEGF-R2 is actively engaged in enhanced VEGF activity in asthma, possibly contributing to an increase in VEGF-induced microvascular remodelling [47]. Interestingly, Feltis et al [47] observed cystic structures within the vessel walls, that they termed angiogenic sprouts. The number of sprouts was markedly increased in asthmatics, and the increase in sprouts per vessel was positively related to the VEGF expression [47].

The angiopoietin family can play a role in vascular remodelling of asthmatic airways. Angiopoietin-1 (Ang-1) is known to stabilize new vessels, while angiopoietin-2 (Ang-2), in the presence of VEGF, acts as an Ang-1 antagonist, making vessels unstable and promoting vessel sprouting [47]. In contrast, endostatin is known to be a strong endogenous inhibitor of angiogenesis [56]. Interestingly, an imbalance between VEGF and endostatin levels was found in induced sputum from asthmatic patients [28]. In biopsies from asthmatic patients, Hoshino et al [52], showed higher expression of basic fibroblast growth factor (bFGF) and angiogenin, with significant correlations between the vascular area and the number of angiogenic factor-positive cells within the airways.

Metalloproteinases (MMPs) can also play a role in the angiogenic processes. MMPs are a large family of zinc- and calcium-dependent peptidases, which are able to degrade most components of tissue extracellular matrix. This function represents an essential requirement to permit cell migration in tissue, lengthening of existing vessels, and sprouting and formation of new vessels. Lee et al. [57] found that levels of VEGF and MMP-9 were significantly higher in the sputum of patients with asthma than in healthy control subjects, as well as a significant correlation between the levels of VEGF and MMP-9 was present. Moreover, administration of VEGF receptor inhibitors reduced the pathophysiological signs of asthma and decreased the expression of MMP-9 [57].

Many inflammatory cells are probably involved as angiogenic growth factor sources in the asthmatic
airways. Mast cells are known to be one of the most important sources of proangiogenic factors [58]. Mast cells can secrete several mediators involved in angiogenesis, such as VEGF, bFGF, TGFβ, MMPs, histamine, lipid-derived mediators, chemokines (IL-8 in particular), cytokines, and proteases (Table 3). Co-localization studies revealed that both tryptase-positive mast cells and chymase-positive mast cells can play a role in the vascular component of airway remodelling in asthma, through induction of VEGF [54,59]. Other studies showed that in asthmatic patients, eosinophils, macrophages and CD34-positive cells can be involved as angiogenic growth factor sources [52,53].

COPD
The microvascular changes in the bronchial mucosa of COPD patients have recently aroused researchers' interest. Bosken et al [60] reported that the airways of patients with COPD were thicker than those of controls. Performing a morphometric analysis, they observed that muscle, epithelium, and connective tissue were all increased in the obstructed patients, and suggested that airway wall thickening contributes to airway narrowing. Kuwano et al. [21] conducted the first study on bronchial vascularity including COPD patients. They observed no difference in vascular area and number of vessels between COPD and controls, so the airway wall thickening in COPD patients was ascribed to an increase in airway smooth muscle. Notably, the lack of difference in vascularity between COPD and controls in the Kuwano study was probably due to the use of Factor VIII, which is not the gold standard to outline vessels [49].

More recently, Tanaka et al [43] assessed the airway vascularity in patients with asthma and COPD using a high-magnification bronchovideoscope and did not find any difference between COPD patients and controls [43]. A drawback of this technique is the detection limit of the bronchovideoscope and the incapacity to detect small vessels, with a size approximately less than 300 μm².

Using immunohistochemistry and staining vessels with anti-CD31 monoclonal antibodies, Hashimoto et al. [17] showed that the number of vessels in the medium and small airways in asthmatic patients was increased, compared to those in COPD patients and controls. Furthermore, the vascular area was significantly increased in the medium airways in asthmatics and in the small airways in COPD patients, as compared to controls. Calabrese et al. [18] performed an immunohistochemical study on bronchial biopsies taken from the central airways of smokers with and without obstruction, using monoclonal antibodies against collagen type IV to outline vessels. They observed an increase both in vascular area and number of vessels in current smokers with COPD and in symptomatic smokers with normal lung function, when compared to healthy non-smokers [18]. In the central airways of clinically stable patients with COPD who were not current smokers, we could demonstrate a higher vascular area, but not an increase in the number of vessels, when compared to control subjects [61]. In spite of the differences in methods and patient selection criteria, all these studies [17,18,61] consistently found an increased vascular area in the airways of patients with COPD (Figure 3).

Interestingly, in a heterogeneous group of COPD patients with different comorbidities, such as lung cancer, bronchiectasis, lung transplantation, and chronic lung abscesses, Polosukhin et al [62] found that reticular basement membrane thickness was increased and the subepithelial microvascular bed was reduced in association with progression from normal epithelium to squamous metaplasia. Recently, a group actively researching this area provided preliminary data which showed the presence of splitting and fragmentation of the reticular basement membrane associated with altered distribution of vascularity between the reticular basement membrane and the lamina propria in COPD patients and smokers as compared to controls [63,64].

Like in asthma, VEGF is implicated in the mechanisms of bronchial vascular remodelling in COPD. Kanazawa et al. [65] showed increased VEGF levels in induced sputum from patients with chronic bronchitis and asthma, and decreased levels from patients with emphysema, as compared to controls. Moreover, VEGF levels were negatively related to lung function in chronic bronchitis, but positively in emphysema, suggesting different actions in these two COPD subtypes [65]. By analysing the bronchial expression of VEGF and its receptors, Kranenburg et al. [66] showed that COPD was associated with increased expression of VEGF in the bronchial, bronchiolar and alveolar epithelium, in macrophages as well as in vascular and airway smooth muscle cells. More recently, Calabrese et al. [18] found an association between increased bronchial vascularity and both a higher cellular expression of VEGF and a vascular expression of α5β3 integrin. Interestingly, α5β3

Table 3 Major mast cells mediators, many of which have angiogenic activity

| Mediators                  | Histamine, Tryptase, Chymase, Heparine, Carboxypeptidase A, MMP-2, MMP-9 |
|----------------------------|---------------------------------------------------------------------------|
| Cytokines                  | IL-3, IL-4, IL-5, IL-6, IL-8, IL-9, IL-10, IL-13, TNFα                     |
| Chemokines                 | RANTES, Eotaxin, MCP-1, MCP-3, MCP-4, IL-8                                 |
| Growth Factors             | VEGF, bFGF, TGFβ, GM-CSF, PDGF, PAF                                       |
| Lipid-derived compounds    | PGD₂, LTD₄, LTC₄, LTD₅, LTE₄                                               |
integrin is an adhesion molecule that is upregulated in new vessel proliferation in response to angiogenic stimuli, while it is not expressed or only at low levels in resting endothelium [67].

An increased expression of FGF-1 and FGF-2 was found by Kranenburg et al. [68] in the bronchial epithelium of COPD patients. Additionally, FGF receptor-1 (FGFR-1) was detected in bronchial epithelial and airway smooth muscle cells and in the endothelium of bronchial vessels. Interestingly, a positive correlation between FGF-1 expression and pack-years was found, indicating that the degree of pulmonary FGF-1 expression may be related to the amount of airway exposure to smoke [68]. The extracellular matrix proteins may play a role in the remodelling of airways and blood vessels in COPD. In COPD patients, as compared to non-COPD patients an increased staining for fibronectin in the neointima, for collagen type IV and laminin in the medial layer, and for collagen type III in the adventitial layer of bronchial vessel walls was observed [69]. Polosukhin et al. [62] showed that in patients with COPD the percentage of HIF-1α positive epithelial cells significantly increased with reduction in blood vessel number, thickness of the reticular basement membrane and increased epithelial height. Other growth factors, involved in vascular changes during chronic inflammatory or neoplastic processes, such as EGF, IGF, PDGF and HGF [70] may also be involved in the vascular component of the bronchial remodelling in COPD, however experimental data are lacking in this area. Similarly, MMPs could also play a role in angiogenesis in COPD, as well as in asthma, however, this area of research has yet to be investigated.

Likely analogous to COPD, but much more rapid in onset, vascular changes may occur after lung transplantation. As reported by Walters and co-workers [9], over recent years attention has been given to airway inflammation and remodelling post lung transplantation. The pathologic airway changes observed show the characteristics of bronchiolitis obliterans syndrome. Angiogenic remodelling seems to occur early and it is not related to airflow limitation. Vessel number and vascular area are higher than in controls, and they are probably related to IL-8 and other C-X-C chemokines rather than VEGF levels [9].

Significance of the vascular component of airway remodelling
Bronchial microvasculature changes may result in airway wall thickening and in the reduction of the lumenal area. Several studies on bronchial vascular remodelling in asthma and COPD showed significant correlations between morphological or biological data (number of vessels, vascular area, expression of angiogenic factors) and lung function parameters, such as FEV1 [17,28,30,45,46,52,53,66,68], FEV1/FVC [29,68] and airway hyperresponsiveness [29,36,45,46]. The functional effects of vascular remodelling may be amplified by
pre-existing airway wall architecture modifications, such as bronchial mucosal thickening, cellular infiltration, collagen deposition and bronchial smooth muscle changes [71,72].

In functional terms, the airway wall can be considered as the sum of three distinct layers and the thickening of each can have separate effects [72]. The thickening of the inner airway wall layer (epithelium, lamina reticularis, and loose connective tissue between the lamina reticularis and the airway smooth muscle (ASM) layer) can amplify the effect of ASM shortening; the thickening of the outer (or adventitial) layer could decrease the static and dynamic loads on the ASM; and an increase in the ASM layer thickness can increase the strength of the muscle. In addition, the remodelling of the connective tissue in the smooth muscle compartment can increase or decrease the amount of radial constraint provided to the ASM. Finally, thickening and fibrous connective tissue deposition in all layers could decrease airway distensibility and allow ASM adaptation in shorter lengths [72].

Hypertrophy and hyperplasia of mucous glandular structures and loss of alveolar attachments are considered to be the main structural changes of airway remodelling in COPD and they may play a crucial role in the functional effects of airway remodelling (Table 4) [73]. However, in COPD patients the exact explanation for the link between structural airway changes, with particular reference to the vascular component, and the functional and clinical consequences are not yet clearly defined and further studies are needed.

**Bronchial vascular remodelling and pharmacological modulation**

The bulk of the literature regarding the pharmacological effects on the vascular component of airway remodelling has been obtained from studies in asthmatic patients. The efficacy of anti-asthma drugs on vascular remodelling is schematically presented in Table 5. Inhaled corticosteroids are the only treatment able to positively affect all three main aspects of the vascular component of air remodelling: vasodilatation, increased microvascular permeability and angiogenesis. Several studies on asthmatic airways indicate that high doses of inhaled corticosteroids (approximately a daily dose of BDP and FP ≥ 800 μg) may reverse the increased vascularity [28,29,42,45,46,54], while there is no consensus on the duration of treatment. Notably, this important effect seems to be especially mediated by a reduced expression of VEGF by inflammatory cells [28-30,54,74].

Less experimental evidence is available on the actions of long-acting β2 agonists (LABAs) and leukotriene receptor antagonists (LTRAs) on decreasing the vascular component of airway remodelling. Three months of treatment with salmeterol, in a placebo-controlled study, showed a significant decrease in the vascularity in the lamina propria of asthmatics [75]. This may have been caused by reduced levels of the angiogenic cytokine IL-8 following salmeterol treatment [76]. Moreover, among anti-leukotrienes, montelukast has proven to have an acute effect on decreasing airway mucosal blood flow, similar to inhaled steroids [77].

There is a dearth of published data regarding the effect of current therapies for COPD on bronchial microvasculature. Recently, in a cross-sectional study on COPD patients, we found that, as compared to untreated patients, treated patients with long-term high doses of beclomethasone showed lower values of vascular area and lower expression of VEGF, bFGF, and TGFβ [61]. Further prospective studies are needed to confirm this finding and to assess the possible role of

---

**Table 5 The efficacy of anti-asthma drugs on aspects of the vascular components of airway remodelling**

|                        | Corticosteroids | LABA | LTRAs |
|------------------------|-----------------|------|-------|
| **Microvascular leakage** | +++             | ++   | +     |
| **Vasodilatation**     | ++              | -    | +     |
| **Angiogenesis**       | +++             | +    | -     |

+++ = highly effective; ++ = effective; + = moderately effective; - = ineffective

N.B.: due to the lack of data regarding theophylline, we excluded it from the table.
bronchodilators on the bronchial microvasculature in COPD.

Finally, several inhibitors of angiogenesis have been studied in vitro and consequently progressed to clinical studies. Some of them have shown promising results in lung cancer, but these molecules have not yet been investigated in chronic airway disease [78]. In the future, these compounds, especially the therapeutic agents that antagonize the effect of VEGF and/or prevent its production could represent a novel approach for positively acting on bronchial microvascular changes in asthma and COPD (Table 6).

Conclusions
In the last two decades there has been an increasing interest in the microvascular changes of bronchial airway mucosa during chronic inflammation, such as asthma and COPD. Up to now, the focus of researchers has been on asthma, while little work has been done in COPD. Moreover, the effects of smoking on bronchial microvascularity need better differentiation from the specific changes due to airflow obstruction.

Although evidence suggests that there are vessel changes in the bronchial wall in both asthma and COPD, there are distinct differences in detail between these situations. Angiogenesis seems to be a typical finding in asthma, while, in COPD, little evidence supports the view that vasodilatation is prevalent.

Microvascular changes in the bronchial airway mucosa are probably the consequence of the activities of many angiogenic factors, but VEGF seems to be crucially involved both in asthma and COPD, and different types of cells can play a role as the source of VEGF.

The clinical and functional relevance of the vascular remodelling remains to be determined both in asthma and COPD; even if some reports suggest that the vascular component of airway remodelling may contribute to worsening of airway function.

There are few data regarding the effects of current therapies on bronchial vascular remodelling. Some longitudinal studies were conducted in asthma, with biopsy quantification of vascular changes. These studies showed that inhaled corticosteroids could effectively act on vascular remodelling in asthmatic airways, partially reversing microvascular changes. Evidence from a cross-sectional study suggests also that long-term treatment with inhaled corticosteroids is associated with a reduction in airway microvascularity in COPD.

Better knowledge about angiogenic processes and their consequences in the airway wall both in asthma and especially COPD are urgently needed, as well as new therapeutic strategies for these conditions.

Acknowledgements
We gratefully acknowledge the help of Dr Carolyn Maureen David in preparing and reviewing the manuscript.
References

1. Widdicombe J: Why are the airways so vascular? Thorax 1993, 48:290-295.

2. Baile EM: The anatomy and physiology of the bronchial circulation. J Aerosol Med 1996, 9:1-6.

3. Charan NB, Baile EM, Pare PD: Bronchial vascular congestion and angiogenesis. Eur Respir J 1997, 10:1173-1180.

4. John GW: Microvascular anatomy of the airways. In Asthma and rhinitis. Edited by: William WB, Stephen TH, Walden, MA: Blackwell Science, , 2, 2000:721-731.

5. Defebach ME: Lung mechanical effects on the bronchial circulation. Eur Respir J Suppl 1990, 125:S86-S90.

6. Lung MAKY, Wang JCC, Cheng KK: The ultrastructure and permeability of tracheobronchial microvascular bed. Chest 2005, 127:696-699.

7. Lieckens S: Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001, 61:253-270.

8. Defebach ME, Charan NB, Lakshminarayan S, Butler J: The bronchial circulation. Small, but a vital attribute of the lung. Am Rev Respir Dis 1987, 135:463-480.

9. Walters EH, Reid D, Soiltan A, Ward D: Increased airway vascularity in the medium and small airways of patients with asthma. Am J Respir Crit Care Med 2005, 171:1125-1130.

10. Salvo G: Quantitative and morphological analysis of the vascular bed in bronchial biopsy specimens from asthmatic and non-asthmatic subjects. Thorax 2001, 56:903-906.

11. Wilson JW, Hi S: The importance of the airway microvasculature in asthma. Eur Respir J Suppl 1996, 11:132-137.

12. Otani K, Kanazawa H, Fujiwara H, Hirata K, Fujimoto S, Yoshikawa J: Increased microvascular permeability and plasma exudation in asthma. Eur Respir J 1990, 3:329-337.

13. McDonald DM: The ultrastructure and permeability of tracheobronchial blood vessels in health and disease. Eur Respir J 1990, 125(Suppl):572-585.

14. Wilson JW, Hii S: Mechanisms of increased airway microvascular permeability and plasma exudation in asthma. Eur Respir J 1990, 3:1053-1041.

15. Meerschaert J, Becky Kelly EA, Mosher DF, Busse WW, Jarjour NN. Segmental antigen challenge increases fibronectin in bronchoalveolar lavage fluid. Am J Respir Crit Care Med 1999, 159:619-625.

16. Svensson C, Groneberg D, Andersson M, Alkner U, Andersson O, Billing B, Gilljam H, Grell F, Persson CGA: Allergen challenge-induced entry of alpha 2-macroglobulin and tryptase into human nasal and bronchial airways. J Allergy Clin Immunol 1995, 96:239-246.

17. Goldie RG, Pedersen KE: Mechanisms of increased airway microvascular permeability: role in airway inflammation and obstruction. Clin Exp Pharmacol Physiol 1995, 22:387-396.

18. James AL, Pare PD, Hogg JC: The mechanics of airway narrowing in asthma. Am Rev Respir Dis 1989, 139:242-246.

19. Otani K, Kanazawa H, Fujihara H, Hirata K, Fukumoto S, Yoshikawa J: Determinants of the severity of exercise-induced bronchoconstriction in patients with asthma. J Asthma 2004, 41:271-278.

20. Roberts WG, Paarde GE: Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1999, 108:2369-2379.

21. Grell F, Wollmer P, Andersson M, Svensson C, Persson CGA: Effects of formoterol on histamine-induced plasma exudation in induced sputum from normal subjects. Thorax 1998, 53:1010-1013.

22. Berman AR, Liu MC, Wagner EM, Proud D: Dissociation of bradykinin-induced plasma exudation and reactivity in the peripheral airways. Am J Respir Crit Care Med 1996, 154:418-423.

23. Cudkowicz L, Leonardo da Vinci and the bronchial circulation. Br J Dis Chest 1933, 47:649-670.

24. Follman J: Clinical applications of research on angiogenesis. New Engl J Med 1995, 333:1951-1957.

25. Chetta A, Zanini A, Torre O, Olivier D: Vascular remodelling and angiogenesis in asthma: morphological aspects and pharmacological modulation. Inflamm Allergy Drug Targets 2007, 7:41-45.

26. Berenger C, Boulet LP: Structural changes in airway diseases. Chest 2006, 129:1068-1087.

27. Hashimoto M, Tanaka H, Abe S: Quantitative analysis of bronchial wall microvascular dimensions in asthma and COPD. Respir Med 2005, 99:1085-1091.

28. Calabrese C, Bocchino V, Varella A, Marzo C, Guaitino C, Mascetti S, Tranfaglia G, Cazzola M, Michel P, Caputi M, Marsico SA: Evidence of angiogenesis in bronchial biopsies of smokers with and without airway obstruction. Respir Med 2006, 100:1415-1422.

29. Dunnill MS: The pathology of asthma with special reference to changes in the bronchial mucosa. J Clin Pathol 1960, 13:27-33.

30. Dunnill MS, Massarella G: Angiogenesis in the bronchi in normal subjects, in status asthmaticus, in chronic bronchitis and in emphysema. Thorax 1960, 15:76-179.

31. Kuwano K, Bokser CH, Paré PD, Bai TR, Wiggs BR, Hogg JC: Small airways dimensions in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis 1993, 148:1220-1225.

32. Kumar SD, Emery MJ, Atkins ND, Danta I, Wanner A: Airway mucosal blood flow in bronchial asthma. Am J Respir Crit Care Med 1998, 158:153-156.

33. Bailey SR, Boustany S, Burgess JK, Hirst SJ, Sharma HS, Simcock DE, Suravaram PR, Weckmann M: Airway vascular reactivity and vasculisation in human chronic airway disease. Pulm Pharmacol Ther 2009, 22:417-425.

34. Charan NB, Johnson SR, Lakshminarayan S, Thompson WH, Carvalho P: Nitric oxide and beta-adrenergic agonist-induced bronchial arterial vasodilation. J Appl Physiol 1997, 82:688-692.

35. Pareti P, Khartonov SA, Barnes PJ: Correlation of exhaled breath temperature with bronchial flow in asthma. Respir Res 2005, 6:15.

36. Chung KF, Rogers DF, Barnes PJ, Evans TW: The role of increased airway microvascular permeability and plasma exudation in asthma. Eur Respir J 1990, 3:1053-1041.

37. McDonald WM: The ultrastructure and permeability of tracheobronchial blood vessels in health and disease. Eur Respir J 1990, 125(Suppl):572-585.

38. Asai K, Kanazawa H, Kamoi H, Shiraishi S, Hirata K, Yoshikawa J: Increased levels of vascular endothelial growth factor in induced sputum in asthmatic patients. Clin Exp Allergy 2003, 33:599-595.

39. Kanazawa H, Nomura S, Yoshikawa J: Role of microvascular permeability on physiologic differences in asthma and eosinophilic bronchitis. Am J Respir Crit Care Med 2004, 169:1125-1130.

40. Kanazawa H, Hirata H, Yoshikawa J: Involvement of vascular endothelial growth factor in exercise induced bronchoconstriction in asthmatic patients. Thorax 2002, 57:885-888.

41. Kanazawa H, Nomura S, Asai K: Roles of angiopoietin-1 and angiopoietin-2 on airway microvascular permeability in asthmatic patients. Chest 2007, 131:1035-1041.

42. Meerschaert J, Becky Kelly EA, Mosher DF, Busse WW, Jarjour NN: Segmental antigen challenge increases fibronectin in bronchoalveolar lavage fluid. Am J Respir Crit Care Med 1999, 159:619-625.

43. Svensson C, Groneberg D, Andersson M, Alkner U, Andersson O, Billing B, Gilljam H, Grell F, Persson CGA: Allergen challenge-induced entry of alpha 2-macroglobulin and tryptase into human nasal and bronchial airways. J Allergy Clin Immunol 1995, 96:239-246.
46. Hoshino M, Takahashi M, Takai Y, Sim J, Aoki N: Inhaled corticosteroids decrease vascularity of the bronchial mucosa in patients with asthma. Clin Exp Allergy 2001, 31:722-730.

47. Felts NB, Wignarajah D, Zheng L, Ward C, Reid D, Harding R, Walters EH: Increased vascular endothelial growth factor and receptors. Am J Respir Crit Care Med 2006, 173:1201-1207.

48. Barbato A, Turato G, Baraldo S, Bazzan E, Calabrese F, Pannocchio Z, Zanin ME, Zunin R, Maestrelli P, Fabbi LM, Saetta M: Epithelial damage and angiogenesis in the airways of children with asthma. Am J Respir Crit Care Med 2006, 174:975-981.

49. Vermeulen PB, Gasparini G, Fox SB, Colpaert C, Marson LP, Gion M, Belien JAM, de Waal RMW, Van Marck E, Magnani E, Weidner N, Harris AL, Drix LX: Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 2002, 38:1564-1579.

50. Vuigt B, Wilson S, Bron A, Holgate ST, Djukanovic R, Aalbers R: Bronchial angiogenesis in severe glucocorticoid-dependent asthma. Eur Respir J 2000, 15:1014-1021.

51. Walters EH, Soltani A, Reid DW, Ward C: Vascular remodelling in asthma. Curr Opinion Allergy Clin Immunol 2008, 8:39-43.

52. Hoshino M, Takahashi M, Aoki N: Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J Allergy Clin Immunol 2001, 107:295-301.

53. Hoshino M, Nakamura Y, Hamid Q: Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma. J Allergy Clin Immunol 2001, 107:1034-1038.

54. Chetta A, Zanini A, Foresti A, D’Ippolito R, Tipsa A, Castagnaro A, Baraldo S, Neri M, Saetta M, Olivieri D: Vascular endothelial growth factor and bronchial wall remodelling in asthma. Clin Exp Allergy 2005, 35:1437-1442.

55. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.

56. O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.

57. Lee KS, Min KH, Kim SR, Park SJ, Park HS, Jin GJ, Lee YC: Vascular endothelial growth factor modulates metalloproteinase-9 expression in asthma. Am J Respir Crit Care Med 2006, 174:161-170.

58. Norbry K: Mast cells and angiogenesis. APAMS 2002, 110:355-371.

59. Zanini A, Chetta A, Saetta M, Baraldo S, D’Ippolito R, Castagnaro A, Neri M, Olivieri D: Chymase-positive mast cells play a role in the vascular component of airway remodelling in asthma. J Allergy Clin Immunol 2007, 120:329-333.

60. Bosken CH, Wiggins BR, Paré PD, Hogg JC: Small airway dimensions in smokers with obstruction to airflow. Am Rev Respir Dis 1990, 142:563-570.

61. Zanini A, Chetta A, Nicollini G, Castagnetti C, D’Ippolito R, Neri M, Olivieri D: Vascular remodelling and inhaled beclomethasone dipropionate in COPD. Thorax 2002, 64:1019-1024.

62. Poloukhis W, Lawson WE, Milestone AP, Eugenova SM, Kulipanov AG, Tchuvakin SG, Masson PP, Balckwsl TT: Association of progressive structural changes in the bronchial epithelium with subepithelial fibrous remodeling: a potential role for hypoxia. Virchows Arch 2007, 451:793-803.

63. Soltani A, Sohal S, Reid D, Muller HK, Weston S, Wood-Baker R, Walters EH: Inhaled corticosteroids in airway remodelling in COPD. Thorax 2009, 64(Suppl 4):ASS.

64. Soltani A, Reid D, Sohal S, Muller HK, Weston S, Wood-Baker R, Walters EH: Vascular and basement membrane remodelling in smokers and COPD. Eur Respir J 2009, Suppl 53: 485.

65. Kanzawa H, Asai K, Harata K, Yoshikawa J: Possible effects of vascular endothelial growth factor in the pathogenesis of chronic obstructive pulmonary disease. Am J Med 2003, 114:354-358.

66. Kranenburg AR, de Boer WJ, Alagappan VKT, Sterk PJ, Sharma HS: Enhanced bronchial expression of vascular endothelial growth factor and receptors (Flk-1 and Flt-1) in patients with chronic obstructive pulmonary disease. Thorax 2005, 60:106-113.

67. Sordi R, Mitola S, Stradi M, Delfippi P, Tarone G, Bussolon F: Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J 1999, 18:882-892.

68. Kranenburg AR, Willems-Widyatusti A, Mooi WJ, Saxena PR, Sterk PJ, de Boer WJ, Sharma HS: Chronic obstructive pulmonary disease is associated with enhanced bronchial expression of FGF-1, FGF-2 and FGFR-1. J Pathol 2005, 206:28-38.

69. Kranenburg AR, Willems-Widyatusti A, Mooi WJ, Sterk PJ, Alagappan VKT, de Boer WJ, Sharma HS: Enhanced bronchial expression of extracellular matrix proteins in chronic obstructive pulmonary disease. Am J Pathol 2006, 162:725-735.

70. Maruotti N, Cantatore FP, Grivelato E, Vacca A, Ribatti D: Angiogenesis in rheumatoid arthritis. Histol Histopathol 2006, 21:557-566.

71. Wilson JW, Kotsimbos T: Airway vascular remodelling in asthma. Curr Allergy Asthma Rep 2003, 3:153-156.

72. Wang L, McParland BE, Paré PD: The functional consequences of structural changes in airways. Chest 2003, 123:3653-3625.

73. Kim V, Rogers TJ, Criner GJ: New concepts in the pathobiology of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008, 5:478-485.

74. Felts BN, Wignarajah D, Reid DW, Ward C, Harding R, Walters EH: Effects of inhaled fluticasone on angiogenesis and vascular endothelial growth factor in asthma. Thorax 2007, 62:314-319.

75. Orsida BE, Ward C, Li X, Bish R, Wilson J, Thien F, Walters EH: Effect of a long-acting β2-agonist over three months on airway wall vascular remodelling in asthma. Am J Respir Crit Care Med 2001, 164:117-121.

76. Reid DW, Ward C, Wang N, Zheng L, Bish R, Orsida BE, Walters EH: Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo. Eur Respir J 2003, 21:994-999.

77. Mendes ES, Campos MA, Hurtado A, Wanner A: Effect of montelukast and fluticasone propionate on airway mucosal blood flow in asthma. Am J Respir Crit Care Med 2004, 169:1131-1134.

78. Horn L, Sandler AB: Angiogenesis in the treatment of non-small cell lung cancer. Proc Am Thorac Soc 2009, 6:206-217.

Cite this article as: Zanini et al.: The role of the bronchial microvasculature in the airway remodelling in asthma and COPD. Respiratory Research 2010 11:132.